Coatue Management 13F: New $36M Stake in Novavax (NVAX)

Coatue Management Takes Position in Novavax, Inc.

Coatue Management added a fresh holding to its portfolio, taking a brand-new stake in Novavax, Inc. (NasdaqGS: NVAX). According to its Form 13F filing with the SEC for the period ended May 15, 2026, the fund bought 3,836,986 shares. Based on an estimated cost basis of $9.18 per share, the transaction carried a total value of approximately $36.1 million.

New Novavax, Inc. Stake Details

Because this investment represents a new purchase, Coatue Management started the period with zero shares and built the position up to 3,836,986 shares by the end of the reporting window. Filings of this type look backward at a prior point in time, meaning this snapshot captures the fund's holdings as of May 15, 2026, and may not reflect its current position today.

Novavax, Inc. Stock Price Context

Shares of Novavax changed hands at $9.42 recently. The stock moves within a 52-week band stretching from a low of $6.20 up to a high of $11.97. The company features a beta of 2.45, reflecting price swings that run hotter than the wider market.

Recent Earnings for Novavax, Inc.

For its financial background, the biotechnology firm posted $413.8 million in revenue, alongside a revenue growth rate of -0.763. Its earnings per share sat at -1.53, accompanied by a net margin of -0.59868 and a return on equity of zero due to negative earnings. The forward P/E ratio is negative, as the company isn't currently profitable on a forward basis. Investors can look toward the next earnings report scheduled for November 5, 2026, for fresh updates.

Insider Buying and Selling at Novavax, Inc.

Company leadership has also been active in the market recently. On June 18, 2026, insider Charles Newton picked up 21,270 shares. This transaction adds context to how internal stakeholders treat company equity, though individual sales or purchases can occur for many personal reasons.

Citigroup Analyst Rating Update

Wall Street firms continue tracking the company closely. On October 15, 2026, Citigroup maintained its sell rating on Novavax while lifting its price target from $7.00 to $8.00. Across the broader analyst community, the stock holds a consensus buy recommendation with a mean price target of $14.00 based on nine analyst opinions.

Inside Novavax, Inc.

Novavax, Inc. is a biotechnology company that researches, discovers, and commercializes vaccines designed to prevent serious infectious diseases. Its products include the Nuvaxovid COVID-19 vaccine and the R21 Matrix-M adjuvant malaria vaccine, supported by collaboration and license agreements with major pharmaceutical partners.

What to Watch at Novavax, Inc.

Market participants will keep an eye out for upcoming SEC disclosures to see how institutional preferences shift over time. Future quarterly reports will also offer clarity on revenue trends and vaccine delivery milestones as the company moves closer to its next earnings release in November.